ConductScience.org, home

Comparison · NCT03371082-5d3ebd2d

Gan & Lee Insulin Glargine Injection vs Lantus®: Number of Subjects With Confirmed Positive AIA After Baseline.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Gan & Lee Insulin Glargine Injection vs Lantus®: Number of Subjects With Confirmed Positive AIA After Baseline. Trial comparisons, record NCT03371082-5d3ebd2d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03371082-5d3ebd2d

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3550.3020.412wilson
Risk in group 20.3560.3030.413wilson
Risk difference, group 1 minus group 2-0.001-0.07880.0768newcombe hybrid score
Risk ratio, group 1 over group 20.9970.81.24log
Odds ratio, group 1 over group 20.9960.7081.4log
Number needed to treat, for one fewer participant with the outcome on Gan & Lee Insulin Glargine Injection than on Lantus®999from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Gan & Lee Insulin Glargine Injection
Gan \& Lee Insulin Glargine Injection for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0-mL pre-filled Gan \& Lee injector pen. Subjects randomized to the Gan \& Lee Insulin Glargine Injection group will participate in the study for 26 weeks.~Gan \& Lee Insulin Glargine Injection: Route of administration: subcutaneous injection
102287OG000
Group 2Lantus®
Lantus® (insulin glargine injection) solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL pre-filled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.~Lantus®: Route of administration: subcutaneous injection
103289OG001

Outcome

Type
SECONDARY
Title
Number of Subjects With Confirmed Positive AIA After Baseline.
Description
The number of subjects in each treatment group with confirmed positive AIA after baseline and up to visit Week 26.
Time frame
Up to Week 26
Population
Safety Analysis Set.

Source ClinicalTrials.gov

Trial

Title
Gan & Lee Insulin Glargine Target Type (1) Evaluating Research
NCT number
NCT03371082
Phases
PHASE3
Conditions
Diabetes Mellitus, Type 1
Interventions
Gan & Lee Insulin Glargine Injection, Lantus®
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Results first posted
2024-05-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03371082-5d3ebd2d